Parents' Experience of Administering Vosoritide: A Daily Injectable for Children with Achondroplasia.

ABSTRACT:

Introduction

Vosoritide is the first approved pharmacological treatment for achondroplasia and is indicated for at-home injectable administration by a trained caregiver. This research aimed to explore parents' and children's experience of initiating vosoritide and administering this treatment at home.

Methods

Qualitative telephone interviews were conducted with parents of children being treated with vosoritide in France and Germany. Interviews were transcribed and analysed using thematic analysis.

Results

Fifteen parents participated in telephone interviews in September and October 2022. The median age of children in this sample was 8 years old (range 3-13 years) and children had been taking treatment from 6 weeks to 13 months. Four themes document families' experienc

SUBMITTER: NiMhurchadha S 

PROVIDER: S-EPMC10129947 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature